| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 81 | Fermented milk nutraceuticals | US986007 | 1997-12-05 | US06156320A | 2000-12-05 | Tamara Georgievna Izvekova; Alexandr Viktorovich Kornilov; Irina Surenovna Amirian |
| Methods for treating or preventing diseases or conditions, which are associated with or caused or contributed to by an opportunistic or pathogenic microorganism in a subject, comprising administering to the subject an effective amount of a culture of lactic acid fermentation microorganisms of the species Lactobacillus acidophilus are disclosed. | ||||||
| 82 | Therapeutic uses of Lactobacillus salivarius LS01 DSM 22775 | EP13166218.1 | 2011-03-07 | EP2626076B1 | 2016-08-24 | Mogna, Giovanni; Strozzi, Gian Paolo; Drago, Lorenzo; Mogna, Luca |
| The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis. | ||||||
| 83 | COMPOSITION COMPRISING PROBIOTIC BACTERIA FOR USE IN THE TREATMENT OF IMMUNE DISORDERS | EP11717732.9 | 2011-03-07 | EP2544698B1 | 2016-05-04 | MOGNA, Giovanni; STROZZI, Gian Paolo; DRAGO, Lorenzo; MOGNA, Luca |
| The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis. | ||||||
| 84 | PROBIOTIC FUNCTIONAL FOOD SUITABLE FOR IMMUNOCOMPROMISED INDIVIDUALS UNDERGOING TREATMENT SUCH AS CHEMOTHERAPY AND/OR RADIOTHERAPY | EP11831903.7 | 2011-10-14 | EP2628394B1 | 2016-04-06 | ORMEÑO SAAVEDRA, María, Loreto; CASTRO INOSTROZA, Erica; BORQUEZ YAÑEZ, Rodrigo; GONZALEZ RIQUELME, Margarita; VERA GARCIA, Rodrigo; TOLEDO AGUILAR, Natalia |
| The invention relates to a probiotic functional food comprising: a biomass of Lactobacillus spp. strains conditioned to withstand temperatures of between -30 and -40 °C, and cryoprotective agents. Said food comprises jellies, desserts, juices and/or milk derivatives, preferably ice cream. This functional food is intended for patients undergoing therapies such as chemotherapy and/or radiotherapy, since it counteracts the side-effects cancer treatment. | ||||||
| 85 | ANTIMICROBIAL PEPTIDE PRODUCED BY INTESTINAL LACTOBACILLUS SALIVARIUS | EP12748662.9 | 2012-07-27 | EP2736924A1 | 2014-06-04 | ROSS, Paul; O'SHEA, Eileen; HILL, Colin |
| An antimicrobial peptide having potent antibacterial activity against Listeria monocytogenes and Staphylococcus aureus is described. Also described is an isolated Lactobacillus salivarius DPC6502 strain as deposited with the National Collection of Industrial and Marine Bacteria under the Accession No. NCIMB 41840, and variants thereof, wherein the isolated bacteria and variants thereof express an antimicrobial peptide having potent antibacterial activity against Lactobacillus delbrueckii subspecies bulgaricus, Listeria and Staphylococcus aureus. | ||||||
| 86 | FOODSTUFF FERMENTED WITH A LACTIC ACID PRODUCING BACTERIA | EP11775817.7 | 2011-09-29 | EP2633084A2 | 2013-09-04 | BROOKS, Peter; BEAL, Jane; SAVVIDOU, Soumelia; DEMECKOVA, Vlasta |
| A fermented foodstuff composition for human consumption is provided, the foodstuff composition being prepared by the fermentation of a foodstuff substrate with a lactic acid producing bacteria, the lactic acid bacteria being characterised by: a) being viable under the conditions prevailing in the human gastrointestinal tract; b) being a bacteria capable of aggregating and/or coaggregating with one or more pathogens; and c) being able to produce upon fermentation in the foodstuff substrate lactic acid in an amount of at least a minimum inhibitory concentration of lactic acid. | ||||||
| 87 | Composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system | EP13166218.1 | 2011-03-07 | EP2626076A1 | 2013-08-14 | Mogna, Giovanni; Strozzi, Gian Paolo; Drago, Lorenzo; Mogna, Luca |
The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis. |
||||||
| 88 | LACTOBACILLUS STRAIN-CONTAINING FOOD COMPOSITE, ORAL CLEANING COMPOSITE AND MEDICAL COMPOSITE FOR INHIBITING ORAL PATHOGENS | US15867301 | 2018-01-10 | US20180206541A1 | 2018-07-26 | Pei-Shan HSIEH; Chung-Wei KUO; Yi-Chun TSAI; Hsieh-Hsun HO; Yi-Wei KUO |
| A food composite, an oral cleaning composite or a medical composite contain at least one lactobacillus strain able to inhibit oral pathogens. The lactobacillus strain is at least one isolated lactobacillus strain selected from a group including Lactobacillus acidophilus F-1 strain; Lactobacillus salivarius subsp. salicinius AP-32 strain; Lactobacillus reuteri GL-104 strain; Lactobacillus paracasei GL-156 strain; Lactobacillus helveticus RE-78 strain; Lactobacillus rhamnosus CT-53 strain; and Lactobacillus paracasei ET-66 strain. The abovementioned lactobacillus strains are able to inhibit oral pathogens and carried by a food composite, an oral cleaning composite or a medical composite. | ||||||
| 89 | Process for the manufacture of pathogen inhibiting bacteria | US15686971 | 2017-08-25 | US09901605B2 | 2018-02-27 | Matthew Ryan Garner; Joseph F. Flint |
| Processes to produce microorganisms that can be incorporated into a microbial-based product that results in high viable cell yields and shelf-stable products are disclosed. These microbial-based products are useful for inhibiting pathogenic growth and as a food additive. A preferred microorganism is a lactic acid producing bacteria. In one embodiment, the process comprises inoculating a lactobacillus fermentation medium with lactic acid producing bacterial cells, harvesting the lactic acid producing bacterial cells at least partially during the log phases, concentrating the lactic acid producing bacterial cells, and preserving the lactic acid producing bacterial cells at a concentration of at least 5×109 cfu/ml. | ||||||
| 90 | LACTOBACILLUS AND BACILLUS BASED DIRECT FED MICROBIAL TREATMENT FOR POULTRY AND METHOD OF USE | US15601656 | 2017-05-22 | US20170333496A1 | 2017-11-23 | Thomas Rehberger; Evan Hutchison; Alexandra Smith |
| This disclosure relates generally to a microbial treatment for poultry. More particularly, the disclosure relates to a direct fed microbial composition including one or more lactic acid bacteria strains in combination with one or more Bacillus bacteria strains configured to inhibit gastrointestinal pathogens in a bird. A method of use is also disclosed herein. | ||||||
| 91 | Fermented infant formula with non digestible oligosaccharides | US14407907 | 2013-06-14 | US09617327B2 | 2017-04-11 | Thomas Ludwig; Sylvie Huybers; Evan Abrahamse; Houkje Bouritius |
| The present invention relates to a fermented infant formulae comprising non digestible oligosaccharides for improving intestinal tract health by decreasing protein digestive effort, by decreasing the amount of endogenously formed proteases concomitant with an increased protein digestion, and a reduced protein fermentation. | ||||||
| 92 | PROCESS AND COMPOSITION FOR MANUFACTURE OF A MICROBIAL-BASED PRODUCT | US15050178 | 2016-02-22 | US20160346337A1 | 2016-12-01 | Matthew Ryan GARNER; Joseph F. Flint |
| Processes to produce microorganisms that can be incorporated into a microbial-based product that results in high viable cell yields and shelf-stable products are disclosed. These microbial-based products are useful for inhibiting pathogenic growth and as a food additive. A preferred microorganism is a lactic acid producing bacteria. In one embodiment, the process comprises inoculating a lactobacillus fermentation medium with lactic acid producing bacterial cells, harvesting the lactic acid producing bacterial cells at mid to late log phase, concentrating the lactic acid producing bacterial cells, and preserving the lactic acid producing bacterial cells at a concentration of at least 5×109 cfu/ml. | ||||||
| 93 | NUTRITIONAL SUPPLEMENT AND PROCESS OF PREPARATION | US15081713 | 2016-03-25 | US20160279090A1 | 2016-09-29 | Anne-Marie Kosi-Kupe |
| Processes for producing a nutritional supplement that contains sulforaphane, and supplements formed thereby. Such a process includes combining a cruciferous vegetable, for example, broccoli sprouts, with at least one strain of Lactobacillus to form a mixture, causing the mixture to undergo lactic fermentation, transform a glucosinolate within the cruciferous vegetable to sulforaphane, and yield a fermented mixture that contains sulforaphane, and then producing from the fermented mixture a supplement that can be ingested by an individual. | ||||||
| 94 | NOVEL COMPOSITIONS | US15092473 | 2016-04-06 | US20160235105A1 | 2016-08-18 | BIRGITTE YDE; Jakob Blenker SVENDSEN |
| The invention relates to a dry compositions for lactic acid bacteria and in particular to a dry composition comprising from 109 to 1013 cfu/g of the composition of lactic acid bacteria cells, wherein the composition is characterized by that it also comprises following amounts of protective agents (all amounts of protective agents below are given relative to 1 g of lactic acid bacteria cells in the composition): from 6 to 9 g of trehalose, from 0.1 to 1 g of inulin and from 0.5 to 3 g of hydrolyzed casein, and by that it does not comprise a salt of alginic acid. The composition has an improved storage stability of the cell of interest. Comparison experiments have been made between compositions with and without alginate and it has been found that there is substantially no difference between compositions with or without alginate with regard to stability. Further, the invention relates to a method for preparing a dry lactic acid bacteria composition. | ||||||
| 95 | FERMENTED INFANT FORMULA WITH NON DIGESTIBLE OLIGOSACCHARIDES | US14407907 | 2013-06-14 | US20150132365A1 | 2015-05-14 | Thomas Ludwig; Sylvie Huybers; Evan Abrahamse; Houkje Bouritius |
| The present invention relates to a fermented infant formulae comprising non digestible oligosaccharides for improving intestinal tract health by decreasing protein digestive effort, by decreasing the amount of endogenously formed proteases concomitant with an increased protein digestion, and a reduced protein fermentation. | ||||||
| 96 | ANITMICROBIAL PEPTIDE PRODUCED BY INTESTINAL LACTOBACILLUS SALIVARIUS | US14234901 | 2012-07-27 | US20140286904A1 | 2014-09-25 | Paul Ross; Eileen O'Shea; Colin Hill |
| An antimicrobial peptide having potent antibacterial activity against Listeria monocytogenes and Staphylococcus aureus is described. Also described is an isolated Lactobacillus salivarius DPC6502 strain as deposited with the National Collection of Industrial and Marine Bacteria under the Accession No. NCIMB 41840, and variants thereof, wherein the isolated bacteria and variants thereof express an antimicrobial peptide of the invention. | ||||||
| 97 | PROBIOTIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND OBESITY-RELATED CONDITIONS | US13964727 | 2013-08-12 | US20140079676A1 | 2014-03-20 | Stephen Francis Olmstead |
| The present invention provides a method and composition for ameliorating or reducing the symptoms and signs and for the treatment of obesity, diabetes, and related conditions in a mammal in need thereof, said method comprising administering effective amounts of a pharmaceutically acceptable composition comprising a mixture of probiotic microorganisms with distinct but complementary pathways of carbohydrate metabolism, for a time sufficient to ameliorate, reduce or treat at least one sign or symptom of obesity, diabetes or cardiovascular disease. Compositions having the desired properties, and methods for their use in pharmaceutical and nutritional formulations, are provided. | ||||||
| 98 | Process and composition for the manufacture of a microbial-based product | US12772137 | 2010-04-30 | US07888062B1 | 2011-02-15 | Matthew Ryan Garner; Joseph Flint |
| Processes to produce microorganisms that can be incorporated into a microbial-based product that results in high viable cell yields and shelf-stable products are disclosed. These microbial-based products are useful for inhibiting pathogenic growth and as a food additive. A preferred microorganism is the lactic acid producing bacteria, Lactobacillus amylovorus M35. In one embodiment, the process comprises inoculating a lactobacillus fermentation medium with M35 cells, harvesting the M35 cells at mid to late log phase, concentrating the M35 cells, and preserving the M35 cells at a concentration of at least 5×109 cfu/ml. | ||||||
| 99 | Probiotic Lactobacillus salivarius strains | US11105590 | 2005-04-14 | US07390519B2 | 2008-06-24 | John Kevin Collins; Gerald Christopher O'Sullivan; Liam O'Mahony; Fergus Shanahan; Barry Kiely |
| A Lactobacillus salivarius strain, AH102, AH103, AH105, AH109 or AH110 or mutants or variants thereof are useful in the prophylaxis and/or treatment of inflammatory activity especially undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome. | ||||||
| 100 | Probiotic lactobacillus salivarius strains | US11105590 | 2005-04-14 | US20060078547A1 | 2006-04-13 | John Collins; Gerald O'Sullivan; Liam O'Mahony; Fergus Shanahan; Barry Kiely |
| A Lactobacillus salivarius strain, AH102, AH103, AH105, AH109 or AH110 or mutants or variants thereof are useful in the prophylaxis and/or treatment of inflammatory activity especially undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome. | ||||||
QQ群二维码
意见反馈
意见反馈